Viewing Study NCT00280956



Ignite Creation Date: 2024-05-05 @ 4:39 PM
Last Modification Date: 2024-10-26 @ 9:22 AM
Study NCT ID: NCT00280956
Status: COMPLETED
Last Update Posted: 2016-06-16
First Post: 2006-01-21

Brief Title: Open Label Natalizumab Safety Extension Study for Subjects With Crohns Disease
Sponsor: Biogen
Organization: Biogen

Study Overview

Official Title: A Phase III Multicenter Open-Label Long-Term Study of the Safety Tolerability and Efficacy of Intravenous Antegren Natalizumab in Crohns Disease Subjects Who Have Previously Participated in Antegren Crohns Disease Studies
Status: COMPLETED
Status Verified Date: 2012-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously IV to subjects with Crohns Disease who have previously participated in studies CD251 CD301 CD303 CD306 or CD307
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None